Page contents Key factsDecisionKey facts Active Substance garetosmab Therapeutic area Congenital, familial and genetic disorders Decision number P/0103/2024 PIP number EMEA-002736-PIP02-23 Pharmaceutical form(s) Solution for infusion Condition(s) / indication(s) Treatment of fibrodysplasia ossificans progressiva Route(s) of administration Intravenous use Contact for public enquiries Regeneron Ireland Designated Activity Company E-mail: clinicaltrials@regeneron.com Tel. +1 9048475385 Decision type P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) Decision date 12/04/2024Share this page